Last Updated: November 16, 2026

Investigational Drug Information for Ruboxistaurin

« Back to Dashboard


What is the drug development status for Ruboxistaurin?

Ruboxistaurin is an investigational drug.

There have been 14 clinical trials for Ruboxistaurin. The most recent clinical trial was a Phase 3 trial, which was initiated on February 1st 2004.

The most common disease conditions in clinical trials are Diabetes Mellitus, Diabetic Neuropathies, and Diabetes Mellitus, Type 2. The leading clinical trial sponsors are Chromaderm, Inc., Eli Lilly and Company, and Heart and Stroke Foundation of Canada.

Recent Clinical Trials for Ruboxistaurin
TitleSponsorPhase
Randomized and Open Label Study for Safety and Efficacy of DBI-102 vs. Vehicle vs. Hydroquinone on Skin Pigmentation and LentigosDermBiont, Inc.Phase 2
Ruboxistaurin in New York Heart Failure Classification III-IV PatientsThe Christ HospitalPhase 1/Phase 2
Ruboxistaurin in New York Heart Failure Classification III-IV PatientsChildren's Hospital Medical Center, CincinnatiPhase 1/Phase 2

See all Ruboxistaurin clinical trials

Clinical Trial Summary for Ruboxistaurin

Top disease conditions for Ruboxistaurin
Top clinical trial sponsors for Ruboxistaurin

See all Ruboxistaurin clinical trials

Ruboxistaurin Development Update, Patent Status, and Market Projection

Last updated: September 6, 2026

Ruboxistaurin is an investigational, orally administered protein kinase C beta inhibitor developed primarily by Eli Lilly for diabetic retinopathy, diabetic macular edema, and diabetic peripheral neuropathy. Its late-stage program did not establish sufficient clinical benefit for regulatory approval. No ruboxistaurin product is approved, marketed, listed in the FDA Orange Book, or generating commercial revenue as of the latest publicly available development record. Its realistic value is therefore tied to a new development strategy, not to an existing commercial franchise.

What is the current development status of ruboxistaurin?

Ruboxistaurin is not an active late-stage commercial development program. Eli Lilly completed several Phase 2 and Phase 3 studies, but the program did not produce an approved indication.

Attribute Status
Generic name Ruboxistaurin
Development code LY333531
Drug class Selective protein kinase C beta inhibitor
Original developer Eli Lilly and Company
Primary targets Diabetic retinopathy, diabetic macular edema, diabetic peripheral neuropathy
Route Oral
Regulatory status Not approved
FDA marketing application No approved NDA
Orange Book status No listed product or patent
Current commercial sales None
Biosimilar status Not applicable; ruboxistaurin is a small molecule
Generic competition No marketed generic because no reference product was approved

The mechanism was designed to reduce abnormal protein kinase C beta signaling associated with hyperglycemia, vascular permeability, retinal damage, and nerve dysfunction. The scientific rationale was strongest in microvascular complications of diabetes, particularly retinal disease and neuropathy.

Why did ruboxistaurin fail to reach approval?

The principal problem was inadequate or inconsistent efficacy in confirmatory trials. Early studies generated signals in diabetic retinopathy and neuropathy, but later trials did not deliver a sufficiently robust benefit-risk profile for approval.

Diabetic retinopathy and macular edema

The PKC-DRS program evaluated ruboxistaurin in patients with diabetic retinopathy. Initial results suggested a reduction in sustained moderate visual loss, particularly among patients with more advanced disease. The effect was not consistently reproduced across subsequent studies at a level likely to support approval.

The drug also entered studies in diabetic macular edema. At the time, the development environment changed rapidly as intravitreal anti-VEGF therapies became the clinical standard. A systemic oral drug needed to demonstrate a clear advantage in vision outcomes, safety, convenience, or combination use. Ruboxistaurin did not establish that position.

Diabetic peripheral neuropathy

Ruboxistaurin was evaluated for diabetic peripheral neuropathy and neuropathic symptoms. The program faced the same development challenge found with many disease-modifying neuropathy candidates: regulatory endpoints required clinically meaningful improvement, while symptom changes and nerve-function measures were difficult to translate into approval-quality evidence.

The program did not produce an approved disease-modifying treatment for diabetic neuropathy. Current management remains dominated by symptomatic medicines and glycemic-risk reduction.

Development timeline

Period Development event
1990s Lilly develops LY333531 as a selective PKC beta inhibitor
Late 1990s to early 2000s Phase 2 studies begin in diabetic retinopathy, macular edema, and neuropathy
Early to mid-2000s Phase 3 PKC-DRS studies evaluate visual-loss outcomes
Mid-2000s Efficacy and regulatory concerns limit progression toward approval
Late 2000s Lilly reduces or ends active commercial development
2010s onward No approved product, major relaunch, or meaningful commercial development emerges

The compound has retained research interest because PKC beta signaling remains relevant to diabetic vascular injury. The clinical asset, however, has not re-entered a credible registration program.

What patents protect ruboxistaurin?

Ruboxistaurin was protected by an older small-molecule patent estate associated with PKC inhibitors and related chemical compounds. The relevant patent families were filed primarily during the 1990s, which places their ordinary U.S. patent-term endpoints broadly in the mid-2010s to early 2020s, depending on the specific family, filing date, patent-term adjustments, continuations, and terminal disclaimers.

Protection category Commercial relevance
Composition-of-matter claims Likely expired or no longer commercially controlling
Salt and formulation claims No known active marketed product to support current exclusivity
Method-of-use claims May have had later expirations, but no approved label currently enforces them
Manufacturing claims No public evidence of a current commercial manufacturing barrier
Orange Book-listed patents None for an approved ruboxistaurin product
Pediatric exclusivity None identified
Regulatory exclusivity None currently available

A precise patent-by-patent expiration schedule is not commercially material unless a sponsor seeks to revive the molecule. The absence of an approved reference product means a future developer would not face a conventional Abbreviated New Drug Application pathway based on an existing FDA-approved ruboxistaurin label.

A new sponsor could pursue patent protection for:

  • A new formulation with improved absorption or tolerability.
  • A sustained-release oral dosage form.
  • Combination therapy with an anti-VEGF agent or glucose-lowering therapy.
  • A new retinal or neuropathy indication.
  • Patient-selection biomarkers.
  • Manufacturing improvements or crystalline forms.
  • A topical, injectable, depot, or ocular delivery system.

Those claims would require new supporting data and could not restore expired composition-of-matter exclusivity.

What is the FDA regulatory and Orange Book status of ruboxistaurin?

Ruboxistaurin has no FDA-approved indication. It is therefore absent from the Orange Book as an approved reference drug.

The regulatory position has four consequences:

  1. There is no approved label for a generic manufacturer to copy.
  2. There is no standard Paragraph IV pathway directed at ruboxistaurin.
  3. There is no Hatch-Waxman market exclusivity period.
  4. There is no FDA-recognized commercial product against which a future generic can establish therapeutic equivalence.

Ruboxistaurin is also not a biologic. Biosimilar competition is not applicable. Any future product would likely require a full new-drug development strategy, unless a sponsor obtained access to an existing regulatory file and could rely on a legally available regulatory pathway.

Are there Paragraph IV challenges, litigation, or settlements?

No material public Paragraph IV litigation, generic challenge, or settlement agreement is associated with an approved ruboxistaurin product.

The absence of Paragraph IV activity follows from the product's regulatory status. Generic companies generally challenge listed patents only after a reference product has been approved and patents have been listed in the Orange Book. Ruboxistaurin has neither an approved reference product nor a current Orange Book patent position.

There is also no established litigation record comparable to the patent disputes surrounding major marketed retinal drugs such as aflibercept, ranibizumab, faricimab, or dexamethasone implants.

How does ruboxistaurin compare with current diabetic retinopathy drugs?

Ruboxistaurin would compete primarily on oral administration and disease-modifying potential. Current retinal treatment is built around local ocular therapy, which produces faster and more established effects for vision-threatening disease.

Therapy Primary use Route Commercial position versus ruboxistaurin
Aflibercept Diabetic macular edema and diabetic retinopathy Intravitreal injection Established efficacy and large commercial base
Ranibizumab Diabetic macular edema and diabetic retinopathy Intravitreal injection Approved retinal standard with biosimilar competition
Faricimab Diabetic macular edema and diabetic retinopathy Intravitreal injection Longer dosing intervals and strong commercial positioning
Dexamethasone implant Macular edema Ocular implant Useful in selected patients, with steroid-related risks
Laser photocoagulation Selected retinal disease Procedure Older but still relevant in certain settings
Ruboxistaurin Investigational diabetic microvascular disease Oral No approval, no sales, no established efficacy advantage

An oral treatment could address adherence and injection burden. It would need to demonstrate that systemic exposure produces clinically meaningful retinal benefit without unacceptable cardiovascular, renal, hepatic, or metabolic toxicity.

What is the commercial market opportunity for ruboxistaurin?

Ruboxistaurin has no current product revenue. Its present market value is therefore zero as a marketed pharmaceutical, although the underlying target remains commercially relevant.

A relaunch would require a differentiated indication. The largest potential markets are:

  • Diabetic macular edema.
  • Nonproliferative diabetic retinopathy.
  • Diabetic peripheral neuropathy.
  • Combination use with intravitreal anti-VEGF therapy.
  • Earlier-stage disease where an oral disease-modifying medicine could delay invasive treatment.

Scenario-based peak-sales estimate

The following is an asset-value scenario, not an established market forecast.

Scenario Development premise Potential peak annual sales
Low Narrow neuropathy indication, modest efficacy, low annual price $100 million to $300 million
Base Oral therapy for selected diabetic retinopathy patients, used with or after ocular therapy $500 million to $1.0 billion
High Demonstrated disease modification, broad retinal label, favorable safety and reimbursement $1.0 billion to $2.0 billion

The base case assumes that ruboxistaurin would be priced below chronic specialty biologics and used in a defined high-risk population rather than across all patients with diabetes. A price in the range of $2,000 to $5,000 per treated patient per year, combined with several hundred thousand to more than one million treated patients globally, could support substantial revenue. Actual uptake would depend on comparative visual outcomes, duration of therapy, payer restrictions, and whether the drug reduced injections or delayed progression.

The high case is difficult to achieve because the retinal market has established injectable competitors with validated visual benefits. An oral mechanism must show more than biological activity. It must improve patient outcomes, reduce treatment burden, or serve patients who are poorly treated by current injections.

How strong is the patent estate for ruboxistaurin?

The legacy patent estate is weak as a current commercial asset because the principal filings are old and no approved product preserves regulatory exclusivity.

Strengths

  • Known pharmacology and clinical safety database.
  • Prior human efficacy data that could support a focused redevelopment strategy.
  • Potential for new formulation and biomarker patents.
  • Oral administration could create a product distinction from injectable retinal therapies.

Weaknesses

  • No active composition-of-matter exclusivity of clear commercial significance.
  • No approved indication.
  • No Orange Book-listed patent position.
  • Prior clinical efficacy was not sufficiently consistent.
  • Current standard of care has advanced materially since the original program.
  • A new sponsor would likely need a modern, indication-specific Phase 2 and Phase 3 program.

Patent strength would improve only through new claims tied to a new formulation, regimen, patient population, combination, or delivery system. Such claims would carry narrower scope and greater validity risk than a broad composition patent.

What manufacturing and intellectual-property barriers exist?

Ruboxistaurin is a small molecule, so manufacturing is not subject to the cell-line, comparability, or cold-chain complexity associated with biologics. The active ingredient could likely be produced through conventional pharmaceutical synthesis if the process is commercially scalable.

The main manufacturing risks are:

  • Re-establishing a reliable, cost-efficient route to the active ingredient.
  • Controlling polymorphism, particle size, and dissolution.
  • Demonstrating long-term stability.
  • Developing a formulation with adequate oral exposure.
  • Avoiding food-effect and drug-interaction problems.
  • Protecting process improvements after legacy composition claims expire.

Manufacturing is unlikely to be the principal barrier. Clinical validation, regulatory strategy, reimbursement, and competitive positioning are more significant.

Which companies could challenge or replace ruboxistaurin?

No company is currently challenging ruboxistaurin through generic litigation because there is no approved reference product. Its competitive threats would come from marketed or advancing therapies in diabetic retinal disease and neuropathy.

The most important retinal competitors include Regeneron and Bayer through aflibercept, Roche through faricimab, and Genentech and biosimilar manufacturers through ranibizumab. Other threats include corticosteroid implants, emerging long-acting ocular delivery technologies, and therapies that target inflammation or retinal vascular stability.

In diabetic neuropathy, competition is less about a single disease-modifying branded drug and more about symptomatic treatments such as duloxetine, pregabalin, gabapentinoids, tricyclic antidepressants, and topical agents.

What generic launch risks exist?

There is no immediate generic launch risk because there is no approved ruboxistaurin product. A future sponsor would face a different risk: off-patent chemistry could allow rapid competition if the sponsor fails to secure enforceable formulation, method-of-use, or process patents.

A new sponsor would also need to determine whether a future product could qualify for:

  • New chemical entity exclusivity, which is unlikely if the same active ingredient was previously approved elsewhere.
  • Orphan-drug exclusivity, if a qualifying rare indication were established.
  • Qualified infectious disease or other special statutory exclusivity, which is not relevant to current development concepts.
  • Three-year clinical-investigation exclusivity for a new indication or formulation, if statutory requirements were met.

The commercial defense would therefore depend more on clinical differentiation, payer adoption, manufacturing scale, and new secondary patents than on legacy ruboxistaurin patents.

Key Takeaways

  • Ruboxistaurin is an unapproved oral PKC beta inhibitor formerly developed by Eli Lilly.
  • Its main programs targeted diabetic retinopathy, diabetic macular edema, and diabetic peripheral neuropathy.
  • Late-stage development did not establish sufficient efficacy for approval.
  • No marketed product, Orange Book listing, Paragraph IV case, or biosimilar pathway exists.
  • Legacy composition patents are old and do not provide a clear current commercial barrier.
  • A redevelopment program would need new clinical evidence and new intellectual property.
  • A realistic peak-sales range is approximately $500 million to $1.0 billion in a successful focused scenario, with a higher range possible only if the drug demonstrates clear disease-modifying or injection-sparing benefits.
  • The main investment risk is clinical validation, not small-molecule manufacturing.

FAQs

Is ruboxistaurin approved by the FDA?

No. The FDA has not approved ruboxistaurin for diabetic retinopathy, diabetic macular edema, diabetic neuropathy, or another indication.

Can a generic company file an ANDA for ruboxistaurin?

Not in the conventional manner because there is no approved ruboxistaurin reference product listed in the FDA Orange Book. A future sponsor would first need an approved reference drug and an applicable regulatory pathway.

Is ruboxistaurin a biologic or biosimilar product?

No. Ruboxistaurin is a chemically synthesized small molecule. Biosimilar regulations do not apply.

Could ruboxistaurin be revived for diabetic neuropathy?

Yes, but revival would require a new clinical program with a clearly defined endpoint and patient population. Prior development history alone would not establish approval readiness.

What would make ruboxistaurin commercially competitive?

The strongest opportunity would be a safe oral therapy that delays retinal progression, reduces the frequency of intravitreal injections, or provides measurable benefit in patients inadequately controlled by anti-VEGF treatment.

References

  1. American Diabetes Association Professional Practice Committee. (2024). Retinopathy, neuropathy, and foot care: Standards of care in diabetes. Diabetes Care, 47(Supplement 1).

  2. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

  3. Food and Drug Administration. (2024). Drugs@FDA. U.S. Department of Health and Human Services.

  4. PKC-DRS Study Group. (2005). Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology.

  5. American Academy of Ophthalmology. (2024). Preferred practice pattern: Diabetic retinopathy. American Academy of Ophthalmology.

  6. ClinicalTrials.gov. (2024). Studies of ruboxistaurin mesylate in diabetic retinopathy, diabetic macular edema, and diabetic peripheral neuropathy. U.S. National Library of Medicine.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.